9-ING-41 (Synonyms: Elraglusib) |
Catalog No.GC39152 |
Le 9-ING-41 est un inhibiteur sélectif et compétitif de la glycogène synthase kinase-3β (GSK-3β) À base de maléimide avec une IC50 de 0,71 μM. 9-ING-41 conduit de manière significative À l'arrêt du cycle cellulaire, À l'autophagie et À l'apoptose dans les cellules cancéreuses. 9-ING-41 a une activité anticancéreuse et a le potentiel d'améliorer les effets antitumoraux des médicaments chimiothérapeutiques.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1034895-42-5
Sample solution is provided at 25 µL, 10mM.
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
[1]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.
Average Rating: 5
(Based on Reviews and 27 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *